GSK has agreed to acquire RAPT Therapeutics in a transaction valued at approximately $2.2 billion, adding ozureprubart, a phase IIb long-acting anti-IgE antibody for food allergy prevention, to its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback